

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 9/10, 47/30, 47/32, 47/34, 47/36</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/04744</b> <b>(43) International Publication Date:</b> 13 February 1997 (13.02.97)
<b>(21) International Application Number:</b> PCT/US96/11766 <b>(22) International Filing Date:</b> 16 July 1996 (16.07.96)  <b>(30) Priority Data:</b> 08/508,577 28 July 1995 (28.07.95) US  <b>(71) Applicants:</b> RUTGERS, THE STATE UNIVERSITY [US/US]; Office of Corporate Liaison and Technology Transfer, Administrative Services Building, Annex II, Bevier Road, P.O. Box 1179, Piscataway, NJ 08855 (US). EMORY UNIVERSITY [US/US]; 1380 South Oxford Road, Atlanta, GA 30322 (US).  <b>(72) Inventors:</b> BROCCCHINI, Stephen; 101 Forest Glen Drive, Highland Park, NJ 08904 (US). HANSON, Stephen, R.; 6032 Kings Mountain Way, Stone Mountain, GA 30087 (US). KOHN, Joachim, B.; 403 Harrison Avenue, Highland Park, NJ 08904 (US).  <b>(74) Agents:</b> BUTCH, Peter, J., III et al.; Lerner, David, Littenberg, Krumholz & Mentlik, 600 South Avenue West, Westfield, NJ 07090 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> POLYMERIC DRUG FORMULATIONS		
<b>(57) Abstract</b>  Polymeric drug formulations containing a non-releasing single-phase dispersion of a water-soluble drug in a water-insoluble tissue-compatible polymer matrix. Polymeric drug formulations are also disclosed containing a single-phase dispersion of a water-soluble drug and a water-insoluble tissue-compatible polymer matrix, and a second, phase-disrupting polymer that is non-miscible with the tissue-compatible polymer and is present in an amount sufficient to form phase-separated microdomains of the second polymer in the tissue-compatible polymer matrix, so that the release rate of the water-soluble drug from the tissue-compatible polymer matrix is related to the amount of the second polymer. Methods of preparing the polymeric drug formulations are also described, as well as methods for site-specific drug delivery utilizing the polymeric drug formulations.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

POLYMERIC DRUG FORMULATIONSTECHNICAL FIELD

The present invention relates to polymeric  
5 drug formulations in the form of solid single-phase  
dispersions of water-soluble drugs in water-insoluble  
tissue-compatible polymer matrices. The present  
invention additionally relates to solid single-phase  
dispersions of water-soluble drugs in water-insoluble  
10 tissue-compatible polymer matrices that include a  
second, phase-disrupting polymer so that  
phase-separated microdomains form in the matrices,  
which results in the release rate of the drug from the  
polymer matrix being affected by the amount of the  
15 second polymer present.

The present invention also relates to methods  
for forming the polymeric drug formulations of the  
present invention in which the water-soluble drug, the  
water-insoluble tissue-compatible polymer and,  
20 optionally, the second phase-disrupting polymer are  
dissolved in a common solvent and then coprecipitated  
by the addition to the solution of a carefully selected  
non-solvent. The resulting coprecipitate is in the  
form of a solid single-phase dispersion of the drug and  
25 polymer with the second polymer, when present, being  
concentrated in phase-separated microdomains. The  
present invention also relates to methods for site-  
specific drug delivery by implanting in the body of a  
patient in need thereof the polymeric drug formulations  
30 of the present invention.

BACKGROUND ART

In the context of this invention, a water-  
soluble drug is defined as a hydrophilic compound with  
a solubility in water greater than 1 percent (w/v) and  
35 that is practically insoluble in nonpolar organic  
solvents such as ethyl acetate, methylene chloride,

chloroform, toluene, or hydrocarbons. Peptide-based drugs represent a particularly important class of water-soluble drugs as defined here.

When such water-soluble drugs are  
5 incorporated into polymers, it is often difficult to prevent the rapid, uncontrolled release of drug in a burst-like fashion from the drug-polymer matrix. This is known as the "burst effect". The burst effect becomes particularly noticeable at high drug loadings.  
10 Within the context of this invention, high levels of drug loading are defined as drug loadings in excess of 10 percent (w/w) based on the weight of drug contained per 100 mg of drug-polymer matrix. The term "lag effect" refers to the phenomenon that the rate of drug  
15 release from a drug-polymer matrix decreases to zero or close to zero, e.g., the release of drug stops for a certain period of time. Burst effects and lag effects are some of the commonly observed phenomena that render drug-polymer matrices unsuitable as "controlled release  
20 systems" for clinical applications.

The physical state of the drug-polymer mixture, also referred to as the morphology of the system, is an often overlooked key parameter in the design of polymeric drug delivery systems. In the  
25 context of the present invention, one can distinguish between the following fundamentally different morphological states: single-phase dispersions and multi-phase dispersions.

In single-phase dispersions the drug is  
30 dispersed within the polymeric phase on a molecular scale. Within the context of this invention, a single-phase dispersion is defined as a drug-polymer matrix that appears transparent and clear to transmitted visible light. This simple requirement indicates that  
35 the drug-polymer matrix is free of microdomains on the length-scale of visible light and therefore does not

scatter transmitted visible light. The formation of a single-phase dispersion requires not only that the drug and polymer have some mutual miscibility, but requires also a method for creating a molecular dispersion of the drug within the polymeric phase. This is an important, often overlooked point: If a drug and polymer particles are simply mixed without creating a molecular dispersion of the drug in the polymer matrix, a single-phase dispersion cannot form, even if drug and polymer are mutually miscible.

In multi-phase dispersions, phase-separated domains exist within the drug-polymer matrix. In multi-phase dispersions, microdomains having dimensions on the length scale of visible light may be present. Within the context of the present invention, such dispersions are readily discerned by the property that the drug-polymer matrices are translucent to visible light, but appear hazy, cloudy, or foggy. Alternatively, the drug may be present in the form of distinct particles or crystals readily discernible by microscopic examination of the drug-polymer matrix. In the extreme case, the drug may be embedded within the polymer in the form of macroscopic particles, readily visible upon inspection by the naked eye.

Hydrophobic polymer matrices of both degradable and nondegradable polymers have been studied as potential vehicles for drug delivery. Although this invention is applicable to both degradable and nondegradable polymers, the following discussion is focused on the more complex degradable systems since the theory of drug release from nondegradable systems is well-known to those skilled in the art. In addition, degradable drug release formulations are generally recognized as particularly useful as implants for the delivery of peptide drugs, which, because of their low oral bioavailabilities and short half-lives

in plasma, cannot be administered by conventional oral and parenteral routes.

Release characteristics from degradable polymer matrices are influenced by several factors, the most important factors being drug loading, the physical state of the drug within the polymeric matrix, and the rate of polymer degradation and erosion as determined by the composition, morphology, and molecular structure of the polymeric matrix.

Drug loading affects the release mechanism and release rate. In the prior art, the simple case of a multi-phase dispersion in which drug particles are dispersed within the polymeric phase is well understood. Briefly, at low loadings, individual drug particles have no contact between each other. Water and/or drug molecules must diffuse through the polymer matrix to allow drug release, which consequently leads to slow release. Drug particles entrapped within the polymeric matrix may not be released at all until polymer degradation leads to the physical erosion of the polymeric matrix. At high loadings, individual drug particles are in physical contact with each other and the dissolution of individual particles results in the formation of discrete pores within the polymeric matrix through which drug is released by slow diffusion (see Siegel and Langer, J. Control. Rel., 14, 153-67 (1990)).

Often, the effect of drug loading is much more complex since the loading level will influence the morphology of the drug-polymer matrix. This point is often overlooked in the prior art. If a drug is only partially miscible with the polymer, a single-phase dispersion may be formed at low loadings. However, as the loading level is raised above the limited miscibility between the drug and the polymer, multi-phase dispersions are formed. At this point, a

dramatic difference in the release mechanism is usually observed. The release rates and mechanisms are particularly difficult to analyze in formulations in which some fraction of the drug forms a single-phase  
5 blend with the polymeric matrix, while another fraction is present in the form of phase-separated domains.

In the prior art it is well-known that control of particle size and homogeneity of the drug dispersion within the polymeric phase is critical in  
10 order to obtain reproducible and prolonged drug release profiles. The formulation of polymeric drug delivery devices for water-soluble drugs as defined above is especially challenging because it is difficult to obtain uniformly dispersed mixtures of such drugs  
15 within a water-insoluble polymeric phase. This is due to the fact that no single solvents are available capable of dissolving the water-soluble drug and the water-insoluble polymeric matrix simultaneously to form a homogeneous solution from which a uniformly dispersed  
20 mixture of drug and polymer may be readily recovered. For that reason, particles of a water-soluble drug are often suspended within a solution of the polymer in an organic solvent such as methylene chloride. Upon solvent casting, the discrete drug particles are  
25 embedded within the polymeric phase in a multi-phase dispersion where the exact distribution of the drug particles is difficult to control and difficult to reproduce. This technique cannot lead to the molecular dispersion of the drug within the polymeric matrix.  
30 Alternative techniques for the formulation of polymeric controlled release devices for water-soluble drugs require the simultaneous co-extrusion or co-molding of drug particles mixed with polymer particles. Such processes are known in the literature but have  
35 significant limitations, namely, the methods are only applicable to drug-polymer combinations that can be

thermally processed below the decomposition temperature of the drug. In addition, these techniques result in the aggregation of drug and polymer in discrete domains that result often in undesirable release profiles.

5           In some cases, careful physical admixture can produce formulations having acceptable release profiles. However, such formulations have release profiles that are complex functions of drug loading levels, size and distribution of drug particles within  
10 the polymeric matrix, and the rate of polymer degradation. For example, instead of extending the duration of drug release, elevated drug loadings usually lead to significant burst effects and an increase in the rate of drug release. Thus, it is  
15 difficult to design a suitable formulation providing an immediate release of drug at a reproducible and acceptable rate, without burst or lag effects with sustained release over extended periods of time. This is but one example of the design limitations inherent  
20 in polymeric drug delivery systems in which the rate of drug release is determined by drug loading, particle size and distribution, and/or polymer degradation.

          Sturesson et al., Intern. J. Pharm., 89, 235-44 (1993), added poly(ethylene glycol) (PEG) to a  
25 poly(lactic acid-co-glycolic acid) matrix to enhance the drug release rate by providing a system with a greater content of water-soluble substances in the polymer matrix, expecting the material to facilitate polymer hydrolysis and promote diffusional release of  
30 the water-soluble drug in the matrix. However, an enhanced rate of drug release was not observed.

          A means by which the effects of particle size and distribution on the release profile can be minimized and by which drug release from a polymeric  
35 matrix may be controlled independent of drug loading or polymer degradation would be highly desirable.

SUMMARY OF THE INVENTION

This need is met by the present invention. It has now been discovered that the drug release rate from single-phase dispersions of water-soluble drugs in water-insoluble tissue-compatible polymer matrices may be controlled by including a second polymer in the tissue-compatible polymer matrix that is non-miscible with the basic polymer matrix, so that phase-separated microdomains of the second polymer are formed in the drug-polymer matrix.

While not being bound by any particular theory, it is believed that the phase-separated microdomains disrupt the monolithic or homogeneous phase of the single-phase drug-polymer dispersion such that the release rate of the drug from the polymer matrix is related to the amount of phase-disrupting second polymer present. The present invention represents a means by which the drug release profile from a polymer matrix may be modified and fine-tuned independent of the level of drug loading, the drug particle size, the distribution of drug particles within the polymeric matrix, or the degradation rate of the tissue-compatible polymer.

The single-phase dispersions of the present invention of water-soluble drugs in water-insoluble tissue-compatible polymer matrices have the unexpected and surprising property that the drug is not released from the drug-polymer matrix to any appreciable extent, even at high loadings. This property is not anticipated by the teachings in the prior art according to which the incorporation of high loadings of a water-soluble drug should have resulted in the observation of a strong burst effect, swelling (due to water-uptake by the drug-polymer matrix), and the rapid release of most of the drug in contact with the matrix surface. Instead, in the single-phase dispersions of the present

invention, drug release occurs only if a second phase-disrupting polymer is added into the formulation.

In the absence of such a phase-disrupting, second polymer, in most instances, the drug will be expressed at the matrix surface without being actually released from the polymeric matrix to any appreciable extent. Such a non-releasing formulation could be useful for some therapeutic applications of water-soluble drugs where the drug is effective as a surface modifying agent. Therefore, according to one aspect of the present invention, a polymeric drug formulation is provided that is a non-releasing single-phase dispersion of a water-soluble drug in a water-insoluble tissue-compatible polymer matrix.

The single-phase dispersions of the present invention are formed by simultaneously dissolving the drug and matrix polymer in an organic solvent system in which the drug and polymer are capable of forming a homogeneous solution. The homogeneous solution of drug and polymer can be used directly for the fabrication of coatings, tubes, filaments or films by appropriate fabrication techniques. Alternatively, the homogeneous solution can be precipitated into a carefully selected non-solvent, resulting in the formation of an intimate, molecularly dispersed co-precipitate of drug and polymer.

Therefore, another aspect of the present invention includes a method of forming a single-phase dispersion of a water-soluble drug with a water-insoluble tissue-compatible polymer. This requires that the drug is miscible in the solid phase with the polymer, and that a solvent system can be identified that is capable of forming a homogeneous solution of the drug and polymer, followed by the addition to the homogeneous solution of a carefully selected non-solvent for the drug and polymer so that the drug

and polymer coprecipitate from the solution as a solid single-phase dispersion of the drug and polymer. This aspect of the present invention also includes polymeric drug formulations prepared by this method of the  
5 invention.

The inclusion of a second phase-disrupting polymer to the drug-polymer matrix to control the drug release profile provides a polymer drug formulation useful in the therapeutic applications of water-soluble  
10 drugs in general and peptide-based drugs in particular. Therefore, yet another aspect of the present invention provides a polymeric drug formulation that is a single-phase dispersion of a water-soluble drug in a water-insoluble tissue-compatible polymer matrix, which  
15 includes a second, phase-disrupting polymer that is non-miscible with the tissue-compatible polymer and is present in an amount sufficient to form phase-separated microdomains of the second polymer in the tissue-compatible polymer matrix, so that the release rate of  
20 the water-soluble drug from the tissue-compatible polymer matrix is related to the amount of the second polymer.

The polymeric drug formulations of the present invention containing a second phase-disrupting  
25 polymer are likewise formed by dissolving the tissue-compatible polymer, drug and second phase-disrupting polymer in a solvent system capable of forming a homogeneous solution of all three components. The homogeneous solution can also be directly fabricated to  
30 provide coatings, tubes, filaments, films, microspheres or other shaped articles, by appropriate fabrication techniques, or precipitated into a non-solvent to form an intimate, molecularly dispersed mixture of the drug, tissue-compatible polymer, and the second phase-  
35 disrupting polymer containing phase-separated

microdomains having dimensions on the length scale of the wavelength of visible light.

Therefore, another aspect of the present invention provides a method of forming a polymeric drug formulation by blending a water-soluble drug with a water-insoluble tissue-compatible polymer and a second, phase-disrupting polymer, that is non-miscible with the drug-delivery polymer, in a solvent system capable of forming a homogeneous solution of the drug, the polymer and the second, phase-disrupting polymer, and adding to the solution an amount of a non-solvent for the drug, the tissue-compatible polymer and the second, phase-disrupting polymer, so that a microdomain-separated solid coprecipitate of the drug, the tissue-compatible polymer and the second, phase-disrupting polymer is formed, wherein the second, phase-disrupting polymer is blended in an amount effective to form separated microdomains. This aspect of the present invention likewise includes polymeric drug formulations prepared by this method of the invention.

The polymeric drug formulations of the present invention are intended for use as medical implants. Therefore, still yet another aspect of the present invention provides a method for site-specific drug delivery by implanting in the body of a patient in need thereof the polymeric drug formulations of the present invention.

The polymeric drug formulations of the present invention are particularly useful when formulated with platelet aggregation inhibiting peptide drugs to improve the clinical performance of stents, the small metal springs used to prevent injured arteries from collapsing during or after angioplasty or other cardiovascular procedures. Typically, stents are placed into an artery, but the metal surface will often result in blood clotting at the stent surface and lead

-11-

to occlusion of the artery. When the polymeric drug formulations of the present invention are loaded with platelet aggregation inhibiting peptide drugs and placed in-between the arterial wall and the stent, the  
5 local release of the platelet aggregation inhibiting peptide drug will reduce the tendency of blood to form clots at the implant site.

The present invention can be used to prepare polymeric films containing up to 30 percent by weight  
10 of a platelet aggregation inhibiting peptide drug. The films are pliable, deformable, soft, elastic and translucent, yet are mechanically strong enough to withstand pulling and deformation during handling. Depending on the exact formulation and amount of the  
15 phase-disrupting second polymer added into the formulation, the films will release biologically active and chemically pure platelet aggregation inhibiting peptide drugs for periods ranging from several hours to several weeks. The mechanical and release properties  
20 of films of the polymeric drug formulations of the present invention containing platelet aggregation inhibiting peptide drugs are ideally suited for placement around an intra-arterial stent.

Methods for site-specific drug delivery in  
25 accordance with the present invention therefore include implanting the polymeric drug formulation of the present invention containing a platelet aggregation inhibiting peptide drug during or following a cardiovascular procedure in which a stent is inserted  
30 into an artery, by placing a film of the drug formulation between the arterial wall and the stent, so that local release of the platelet aggregation inhibiting peptide drug will reduce the formation of blood clots at the stent insertion site.

35 Polymeric drug formulations according to the present invention containing platelet aggregation

inhibiting peptide drugs are also useful in the formulation of a wider range of medical devices and implants that come in contact with blood. Whenever a blood-contacting device is used for any length of time, the patient has to undergo anticoagulation therapy to prevent the formation of blood clots at the device surface. The acute thrombogenicity of artificial surfaces can be reduced by the release of a platelet aggregation inhibiting peptide drug from the device surface. Therefore, the polymeric drug formulations of the present invention containing an anti-thrombotic peptide drug can be used to form coatings on existing device surfaces by dipping or spray-coating techniques. Specific applications include the reformulation of the surface of vascular grafts, the formulation of new blood bags, and the reduction of the thrombogenic potential of tubings and membranes that come in contact with blood in extracorporeal devices.

Therefore, methods for site-specific drug delivery in accordance with the present invention will also include implanting in the body of a patient a blood-contacting device or implant coated with the polymeric drug formulation of the present invention in which the drug is a platelet aggregation inhibiting peptide drug. The present invention therefore also includes blood-contacting devices or implants coated with the polymeric drug formulation of the present invention in which the drug is a platelet aggregation inhibiting peptide drug.

A more complete appreciation of the invention and many more other intended advantages can be readily obtained by reference to the following detailed description of the preferred embodiment.

#### BEST MODE OF CARRYING OUT THE INVENTION

The polymeric drug formulations of the present invention are based on well-known tissue-

compatible polymers. Depending upon the intended end-use, the tissue-compatible polymer may be degradable or non-degradable under physiological conditions. The polymer to be used in this invention has to be readily  
5 soluble in a wide range of solvents and chemically compatible with the drug to be delivered. Suitable candidate materials for use in this invention are the previously-described degradable poly(carbonates) disclosed by U.S. Patent No. 5,099,060, the  
10 poly(iminocarbonates) described by U.S. Patent No. 4,980,449 and the poly(arylates) disclosed by U.S. Patent No. 5,216,115. The disclosures of all three patents are incorporated herein by reference. The tyrosine dipeptide-derived poly(carbonates),  
15 poly(imino-carbonates) and poly(arylates) disclosed therein are preferred, with tyrosine dipeptide-derived poly(arylates) being particularly preferred. The most preferred tyrosine dipeptide derived poly(arylate) is poly(desaminotyrosyl-tyrosine hexyl ester adipate)  
20 (poly(DTH adipate)). Poly(DTH adipate) having a weight-average molecular weight ranging between about 80,000 and about 200,000 daltons is particularly preferred.

Other well-known tissue-compatible polymers  
25 that may be used include poly(lactic acid), poly(glycolic acid), and co-polymers thereof, poly(ethylene-co-vinyl acetate), (commonly referred to by its abbreviation EVA), poly(caprolactone), poly(orthoesters), poly(vinyl-pyrrolidone), pyran copolymer,  
30 poly(hydroxypropyl-methacrylamide-phenol), poly(hydroxyethyl-aspartamide-phenol), poly(ethylene oxide)-poly(lysine) substituted with palmitoyl residues, poly(hydroxybutyric acid), poly(acetals), poly(dihydropyran), poly(cyanoacrylates) and cross-linked and  
35 amphipathic block copolymers of hydrogels, and the like. The polymer molecular weight will depend upon

the requirements of the intended end use of the polymeric drug formulation. The polymer molecular weight is one factor to be considered for drug compatibility and an appropriate polymer molecular weight can be readily determined by one of ordinary skill in the art without undue experimentation.

In addition to being chemically compatible with the tissue-compatible polymer, drugs for use in the polymeric drug formulations of the present invention must possess at least some solubility in the non-aqueous solvent systems of the present invention and must be chemically stable in the solvent systems. While the polymeric drug formulations are particularly well-suited for the delivery of peptide drugs, non-peptide drugs may be used as well. Examples of suitable non-peptide drugs include natural and unnatural antibiotics, cytotoxic agents, and oligonucleotides.

The polymeric drug formulations in the present invention are particularly well-suited for the delivery of peptide drugs and overcome some of the difficulties encountered in previous attempts to formulate controlled release devices that show reproducible release profiles without burst and/or lag effects, and the premature deactivation of the drug during fabrication of the device. The peptide drugs suitable for formulation with the compositions of the present invention include natural and unnatural peptides, oligopeptides, cyclic peptides, library generated oligopeptides, polypeptides, and proteins, as well as peptide mimetics and partly-peptides, as long as the specific drug moiety has some solubility in a single solvent or solvent mixture such that the drug moiety and the water-insoluble polymer can form a homogenous solution. The peptide drugs may be obtained

-15-

by some form of chemical synthesis or be naturally produced or be obtained by recombinant genetics.

Suitable peptide drugs include immunoglobulins and immunoglobulin fragments. Peptide  
5 drugs of particular interest include platelet aggregation inhibiting peptides, which are antagonists of the cell surface glycoprotein IIb/IIIa, thus preventing platelet aggregation and ultimately clot formation. Preferred platelet aggregation inhibiting  
10 (PAI) peptides include the PAI peptides disclosed by published PCT Application No. WO 90/15620, the disclosure of which is incorporated herein by reference.

The following PAI peptides are particularly  
15 preferred:

PAI 1: E-C-A-D-G-L-C-C-D-Q-C-R-F-L-K-K-G-  
T-V-C-R-V-A-K-G-D-W-N-D-D-T-C-T-G-Q-S-C-D-C-P-R-N-G-L-  
Y-G

PAI 2: E-E-P-C-A-T-G-P-C-C-R-R-C-K-F-K-R-  
20 A-G-K-V-C-R-V-A-K-G-D-W-N-N-D-Y-C-T-G-K-S-C-D-C-P-R-N-  
P-W-N-G

PAI 3: G-C-G-K-G-D-W-P-C-A-NH<sub>2</sub>

PAI 4: G-C-K-G-D-W-P-C-A-NH<sub>2</sub>

PAI 5: C-G-K-G-D-W-P-C-NH<sub>2</sub>

25 PAI 7: C-K-G-D-W-C-A-NH<sub>2</sub>

PAI 9: Mpr-K-G-D-Pen-NH<sub>2</sub>

PAI 10: C-K-G-D-W-P-C-NH<sub>2</sub>

PAI 12: C-K-G-D-W-P-C-NH<sub>2</sub>

PAI 13: C-K-G-D-F-P-C-NH<sub>2</sub>

30 PAI 14: C-K-G-D-L-P-C-NH<sub>2</sub>

PAI 15: C-K-G-D-V-P-C-NH<sub>2</sub>

PAI 16: C-K-G-D-Y(OMe)-P-C-NH<sub>2</sub>

PAI 17: C-K-G-D-(2-Nal)-P-C-NH<sub>2</sub>

PAI 18: C-K-G-D-(Cha)-P-C-NH<sub>2</sub>

35 PAI 19: Mpr-K-G-D-W-P-C-NH<sub>2</sub>

PAI 20: Mpr-K-G-D-Y-P-C-NH<sub>2</sub>

	PAI 21:	Mpr-K-G-D-F-P-C-NH <sub>2</sub>
	PAI 22:	Mpr-K-G-D-L-P-C-NH <sub>2</sub>
	PAI 23:	Mpr-K-G-D-V-P-C-NH <sub>2</sub>
	PAI 24:	Mpr-K-G-D-Y(OMe)-P-C-NH <sub>2</sub>
5	PAI 25:	Mpr-K-G-D-(2-Nal)-P-C-NH <sub>2</sub>
	PAI 26:	Mpr-K-G-D-(Cha)-P-C-NH <sub>2</sub>
	PAI 27:	cyclo(G-K-G-D-W-P)
	PAI 28:	cyclo(A-K-G-D-W-P)
	PAI 29:	cyclo(A <sup>†</sup> -K-G-D-W-P)
10	PAI 30:	cyclo(F-K-G-D-W-P)
	PAI 31:	cyclo(beta-Ala-K-G-D-W-P)
	PAI 32:	cyclo(gamma-Abu-K-G-D-W-P)
	PAI 33:	cyclo(R-K-G-D-W-P)
	PAI 34:	C-K-G-D-W-G-C-NH <sub>2</sub>
15	PAI 37:	C-K-A-D-W-P-C-NH <sub>2</sub>
	PAI 39:	C-K-G-D-W-(Sar)-C-NH <sub>2</sub>
	PAI 41:	C-K-G-D-I-P-C-NH <sub>2</sub>
	PAI 42:	C-K-G-D-(4-Cl-Phe)-P-NH <sub>2</sub>
	PAI 43:	C-K-(Sar)-D-W-P-C-NH <sub>2</sub>
20	PAI 44:	C-K-G-D-(4-NO <sub>2</sub> -Phe)-P-C-NH <sub>2</sub>
	PAI 47:	Acetyl-C-K-G-D-W-P-C-NH <sub>2</sub>
	PAI 48:	Mpr-K-G-D-W(Formyl)-P-C-NH <sub>2</sub>
	PAI 49:	Mvl-K-G-D-W-P-C-NH <sub>2</sub>
	PAI 51:	Mpr-K-G-D-W-P-Pen-NH <sub>2</sub>
25	PAI 52:	Mpr-K-G-D-W-P-Pen <sup>†</sup> -NH <sub>2</sub>
	PAI 54:	Mpr-K-G-D <sup>†</sup> -W-P-Pen-NH <sub>2</sub>
	PAI 55:	Mpr-K-G-D-W-(Thz)-C-NH <sub>2</sub>
	PAI 56:	Mpr-K-G-D-H(2,4-DNP)-P-C-NH <sub>2</sub>
	PAI 57:	Mpr-K-G-D-(2-Nal)-P-Pen-NH <sub>2</sub>
30	PAI 58:	Mvl-K-G-D-W-P-Pen-NH <sub>2</sub>
	PAI 59:	Mpr-K-G-D-W-(Pip)-Pen-NH <sub>2</sub>
	PAI 60:	Mpr-(Har)-G-D-W-P-C-NH <sub>2</sub>
	PAI 61:	Mpr-K-G-D-W-P-C <sup>†</sup> -NH <sub>2</sub>
	PAI 62:	Mpr-K <sup>†</sup> -G-D-W-P-Pen-NH <sub>2</sub>
35	PAI 63:	Mpr-(Har)-G-D-W-P-Pen-NH <sub>2</sub>
	PAI 64:	Mpr-(Acetimidyl-Lys)-G-D-W-P-C-NH <sub>2</sub>

-17-

- PAI 65: Mpr-(Acetimidyl-Lys)-G-D-W-P-Pen-NH<sub>2</sub>
- PAI 66: Mpr (N<sup>G</sup>,N<sup>G'</sup>-ethylene-Har)-G-D-W-P-C-NH<sub>2</sub>
- PAI 67: Mpr (N<sup>G</sup>,N<sup>G'</sup>-ethylene-Har)-G-D-W-P-Pen-NH<sub>2</sub>
- PAI 68: Mpr-Har-Sar-D-W-P-C-NH<sub>2</sub>
- PAI 69: Mpr-(Acetimidyl-Lys)-G-D-W-P-Pen-NH<sub>2</sub>
- PAI 70: Mpr-(Phenylimidyl-Lys)-G-D-W-P-C-NH<sub>2</sub>
- PAI 71: Mpr-Har-Sar-D-W-P-PenNH<sub>2</sub>
- PAI 72: Mpr-(Phenylimidyl-Lys)-G-D-W-P-PenNH<sub>2</sub>
- PAI 73: Mpr-Har-G-D-W-(3,4-dehydro-Pro)-C-NH<sub>2</sub>
- PAI 74: Mpr-Har-G-D-Pen-NH<sub>2</sub>
- PAI 75: Mpr-(Phenylimidyl-Lys)-G-D-Pen-NH<sub>2</sub>

PAI peptides are chemically compatible with poly(DTH adipate) disclosed by U.S. Patent No. 5,216,115. Pliable, deformable, soft, elastic and transparent films of poly(DTH adipate) containing up to 30 percent by weight of PAI peptides can be produced according to the methods of the present invention.

The chemical compatibility of drugs with tissue-compatible polymers can be readily determined by one of ordinary skill in the art without undue experimentation. Methods to evaluate chemical compatibility between the polymer and a drug moiety have been described for the case of polyanhydrides by K. W. Leong, P. D. Amore, M. Marlett, and R. Langer, J. Biomed. Mater. Res., 20, 51-64 (1986). These methods are generally applicable and involve the fabrication of drug-loaded polymeric matrices by several techniques, followed by the evaluation of polymer molecular weight, drug purity, and the identification of any newly formed chemical species by HPLC, FT-IR or other analytical techniques.

An important issue is the evaluation of mutual miscibility between the polymer and the drug. According to the present invention, the drug moiety and the polymeric matrix must be miscible (blendable) in the solid state. The theoretical criteria (as well-known to anyone skilled in the art-see Billmeyer, Textbook of Polymer Science) for miscibility is a shift in the polymer glass transition temperature upon mixing of the drug with the polymer. An empirical criteria, as defined here within the context of this invention, is that upon solvent casting, extrusion, or compression molding a mixture of polymer and drug, a transparent device is obtained that is free of discrete drug particles visible to the naked eye. Transparency of the device indicates that the drug loaded polymeric matrix does not contain phase separated microdomains on the length scale of visible light, while a translucent device having a foggy, cloudy, or hazy appearance can be assumed to contain phase-separated microdomains on the length scale of visible light.

The polymer drug formulations of the present invention may contain drug loadings from trace levels to about 50 percent by weight. Higher drug loadings will be useful only in rare circumstances. Preferably, the compositions contain a therapeutically effective amount of the drug. Drug loading levels of about 30 percent by weight may be employed without detracting from the mechanical properties of films and coatings formed from the compositions of the present invention. Most preferred embodiments are expected to have drug loadings from about 10 to 20 percent by weight.

The polymeric drug formulations of the present invention may optionally include a second, phase-disrupting polymer that is non-miscible with the tissue-compatible polymer. The term "non-miscible" is used in its ordinary sense with respect to the two

polymers as defined by Billmeyer, Textbook of Polymer Science (3rd Ed., John Wiley & Sons, 1984).

One of ordinary skill in the art can easily select a second, phase-disrupting polymer that is non-miscible with a tissue-compatible polymer without undue experimentation. As a general rule, since the tissue compatible matrix polymer is water-insoluble, water-soluble polymers are good candidates for use as phase-disrupting polymers since these materials will usually be non-miscible with the matrix polymer. Water-solubility is additionally expected to be a favorable property for the phase disrupting polymer since it can enhance the observed release rate of the drug from the drug-polymer matrix. Examples of suitable non-miscible polymers include poly(alkylene oxides) such as poly(ethylene glycol) (abbreviated: PEG), polysaccharides, poly(vinyl alcohol), polypyrrolidone, poly(acrylic acid) and its many water-soluble derivative such as poly(hydroxyethyl-methacrylate), and the like. The present invention also contemplates the use of non-polymeric materials that are non-miscible with the tissue-compatible polymer and result in the formation of phase-separated microdomains.

As a general rule, the exact molecular weight of the phase-disrupting polymer is not a critical parameter and needs to be determined on a trial and error basis, using phase-disrupting polymer preparations of different molecular weights and observing the resulting release profiles. However, this can be performed by one of ordinary skill in the art without undue experimentation.

Molecular weights in the range of about 1,000 daltons to several hundred thousand daltons are useful. One of ordinary skill in the art can determine the optimal molecular weight of the phase-disrupting polymer needed to obtain the required release profile

suitable for any given medical application. PEG is particularly well suited for use in combination with poly(DTH adipate) and PAI peptide. PEG having a weight-average molecular weight ranging between about 5 1,000 and about 2,000 daltons is particularly preferred. When PEG is used as the second phase-disrupting polymer, it should be present at a level between about 2 and about 30 percent by weight. A level between about 5 and about 15 percent by weight is 10 preferred, with a level of about 10 percent by weight being most preferred.

As the concentration of the second, phase-disrupting polymer increases in the formulation, the rate of drug release from the polymer matrix will also 15 increase, although this relationship is not linear. The drug release rate selected will depend upon the therapeutic dosage profile required for the drug to be delivered. However, this also can be readily determined by one of ordinary skill in the art without 20 undue experimentation.

The polymeric drug formulations of the present invention are prepared by simultaneously dissolving the tissue-compatible polymer, drug and optional second, phase-disrupting polymer in an organic 25 solvent system capable of forming a homogenous solution of the tissue-compatible polymer, drug and second polymer, if present. Typical solvent systems will include one or more solvents selected from methanol, methylene chloride, ethanol, ethylene glycol, glycerol, 30 tetrahydrofuran, ethyl acetate, acetonitrile, acetone, diisopropyl ether, methyl t-butyl ether, chloroform, carbon tetrachloride, dichloroethane, and water. Individual drug and polymer components must possess a solubility in at least one of the solvents of at least 35 1 g/l. The solvents may be pre-blended before the drug and the polymer(s) are dissolved therein.

Alternatively, drug or polymer may be dissolved in the individual solvent in which it is most soluble, after which the solutions are combined to form a solvent system in which the drug and polymer(s) are dissolved.

5           The drug and polymer(s) should be dissolved in the mixing solvents at a level preferably between about 1 and about 30 percent by weight, and preferably between about 5 and about 20 percent by weight. A concentration between about 5 and about 10 percent by  
10 weight is most preferred.

          The relative solubilities of the drugs and polymers intended for use with the present invention in various organic solvents are well-known chemical properties. The selection of an organic solvent system  
15 in which a drug, a tissue-compatible polymer and optionally a second, phase-disrupting polymer are forming a homogeneous solution at their respective concentrations may be readily determined without undue experimentation.

20           Briefly, using the known solubility profiles of each individual component, one would first consider a simple mixture of each of the individual solvents. For example, if the drug has some solubility in acetone, the phase-disrupting polymer is soluble in  
25 methanol, and the tissue compatible polymer is soluble in methylene chloride, a mixture of acetone, methanol, and methylene chloride would be the initial starting point for the development of a solvent system that can dissolve all three of the components in a homogenous  
30 solution. Next, hydrogen bonding effects, polarity effects, and common solvent effects are considered. Inspection of the well-known solubility parameters (as listed in any comprehensive solvent information source such as the CRC Handbook of Physics and Chemistry) also  
35 assists in finding suitable solvent mixtures for all three solutes. The identification of complex solvent

mixtures for different solutes is a well-known task in the formulation of numerous pharmaceutical and cosmetic products and can be readily accomplished by anyone skilled in the art.

- 5                   Compositions in accordance with the present invention in which a PAI peptide is the drug, poly(DTH adipate) is the tissue-compatible polymer and PEG is the second, phase-disrupting polymer, may be prepared by dissolving the PAI peptide and PEG in separate
- 10 quantities of methanol, which solutions are then combined. The poly(DTH adipate) may then be dissolved in methylene chloride, with the methylene chloride solution then being combined with the methanol solution.
- 15                   The solution of drug and polymer(s) is then precipitated into a non-solvent to form the sold single-phased dispersion of the drug in the tissue-compatible polymer, optionally including phase-separated microdomains caused by the presence of the
- 20 second phase-disrupting polymer. The non-solvent should be miscible with the solvents which were used to dissolve drug and polymer(s). Using a non-solvent for the precipitation that is not fully miscible with each of the solvents used to dissolve drug and polymers
- 25 carries the danger of obtaining a separation of the solvent mixture into two phases during the precipitation process. Although this may be acceptable in some circumstances, this is not the preferred mode of conducting the precipitation step. For example,
- 30 during early experiments, a homogeneous solution of a peptide drug and a polymer was dissolved in a mixture of methanol and methylene chloride. When this homogeneous solvent mixture was added into hexane used as the precipitation non-solvent, the solvent mixture
- 35 separated into two layers since methanol and hexane are not fully miscible in all proportions. This prevented

the precipitation of a suitable single-phase drug-polymer matrix. Examples of suitable non-solvents include ethers such as diethyl ether, diisopropyl ether, methyl t-butyl ether, and the like, as well as  
5 methyl ethyl ketone, acetone, ethyl acetate, acetonitrile, toluene, xylene, carbon tetrachloride and the like. A copious excess of the non-solvent of at least between 5-10 volumes compared to the volume of the dissolving solvents should be employed, and the  
10 non-solvent may be chilled as low as the freezing point of the non-solvent to promote the co-precipitation.

The coprecipitated drug-polymer matrices are dried to remove any residual solvent and are then fabricated by known methods to produce a variety of  
15 useful articles. Depending on the thermal stability of the drug and the polymer, the articles can be shaped by conventional polymer-forming techniques such as extrusion, compression molding, injection molding and the like to form implantable drug delivery devices.

20 Poly(DTH adipate) films containing between trace amounts and 30 percent by weight of PAI peptides (as the drug) and between trace amounts and about 30 percent by weight of PEG (as the phase-disrupting polymer) can be inserted between an arterial stent and  
25 artery wall to prevent blood clotting at the stent surface and the consequential arterial occlusion. The same composition can also be formed as a coating on the surface of medical devices and implants that come in contact with blood by conventional dipping or spray  
30 coating techniques to prevent the formation of blood clots on the device or implant surface. Implantable drug delivery devices formed from the polymeric drug formulations of the present invention may otherwise be implanted in the body of a patient in need thereof for  
35 site-specific drug delivery by procedures that are

essentially conventional and well-known to those of ordinary skill in the art.

In the management of thrombotic disorders the polymeric drug formulations of this invention may be  
5 utilized in a variety of shaped articles. Subjects in need of treatment (typically mammalian) using the polymeric drug formulations of this invention can be administered drug dosages that will provide optimal efficacy. The dose and method of administration will  
10 vary from subject to subject and be dependent upon such factors as the type of mammal being treated, its sex, weight, diet, concurrent medication, overall clinical condition, the particular compounds employed, the specific use for which these compounds are employed,  
15 and other factors which those skilled in the medical arts will recognize.

The polymeric drug formulations of this invention may be prepared for storage under conditions suitable for the preservation of drug activity as well  
20 as maintaining the integrity of the polymers, and are typically suitable for storage at ambient or refrigerated temperatures.

The drug components to be incorporated in the polymeric drug formulations of this invention may be  
25 provided in a physiologically acceptable carrier, excipient, stabilizer etc., and may be provided in sustained release or timed release formulation supplemental to the polymeric formulation prepared in this invention. Acceptable carriers or diluents for  
30 therapeutic use are well known in the pharmaceutical field, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co., (A.R. Gennaro edit. 1985). Such materials are nontoxic to the recipients at the dosages and concentrations  
35 employed, and include buffers such as phosphate, citrate, acetate and other organic acid salts,

antioxidants such as ascorbic acid, low molecular weight (less than about ten residues) peptides such as polyarginine, proteins, such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as poly(vinylpyrrolidinone), amino acids such as glycine, glutamic acid, aspartic acid, or arginine, monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose or dextrans, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, counterions such as sodium and/or nonionic surfactants such as Tween, Pluronics or polyethyleneglycol.

Dosage formulations of the compositions of this invention to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile membranes, or by other conventional methods such as irradiation or treatment with gases or heat. The pH of the compositions of this invention typically will be between 3 and 11, and more preferably from 5 to 9.

While the preferred route of administration for the cardiovascular applications of the polymeric drug formulations of this invention is by surgical implantation of a shaped article or film into a blood vessel, other methods of administration are also anticipated such as subcutaneously, intramuscularly, colonically, rectally, nasally or intraperitoneally, employing a variety of dosage forms such as suppositories, implanted pellets or small cylinders, aerosols, oral dosage formulations and topical formulations such as ointments, drops and dermal patches.

The compounds of this invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.

The polymeric drug formulations of this invention are suitable for applications where localized drug delivery is desired, as well as in situations where a systemic delivery is desired.

5           The drugs incorporated into the formulations of this invention may desirably further incorporate agents to facilitate their delivery systemically to the desired drug target, as long as the delivery agent meets the same eligibility criteria as the drugs  
10 described above. The active drugs to be delivered may in this fashion be incorporated with antibodies, antibody fragments, growth factors, hormones, or other targeting moieties, to which the drug molecules are coupled.

15           The polymeric drug formulations of this invention may be formed into shaped articles, such as valves, stents, tubing, prostheses and the like.

          Therapeutically effective dosages may be determined by either in vitro or in vivo methods. For  
20 each particular compound of the present invention, individual determinations may be made to determine the optimal dosage required. The range of therapeutically effective dosages will naturally be influenced by the route of administration, the therapeutic objectives,  
25 and the condition of the patient. For the various suitable routes of administration, the absorption efficiency must be individually determined for each drug by methods well known in pharmacology. Accordingly, it may be necessary for the therapist to  
30 titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. The determination of effective dosage levels, that is, the dosage levels necessary to achieve the desired result, will be within the ambit of one skilled in the  
35 art. Typically, applications of compound are commenced at lower dosage levels, with dosage levels being

increased until the desired effect is achieved. The release rate of the drug from the formulations of this invention are also varied within the routine skill in the art to determine an advantageous profile, depending  
5 on the therapeutic conditions to be treated.

A typical dosage might range from about 0.001 mg/kg to about 1000 mg/kg, preferably from about 0.01 mg/kg to about 100 mg/kg, and more preferably from about 0.10 mg/kg to about 20 mg/kg. Advantageously,  
10 the compounds of this invention may be administered several times daily, and other dosage regimens may also be useful.

In practicing the methods of this invention, the compounds of this invention may be used alone or in  
15 combination, or in combination with other therapeutic or diagnostic agents. In certain preferred embodiments, the compounds of this inventions may be coadministered along with other compounds typically prescribed for these cardiovascular conditions  
20 according to generally accepted medical practice, such as anticoagulant agents, thrombolytic agents, or other antithrombotics, including platelet aggregation inhibitors, tissue plasminogen activators, urokinase, prourokinase, streptokinase, heparin, aspirin, or  
25 warfarin. The compounds of this invention can be utilized in vivo, ordinarily in mammals such as primates, such as humans, sheep, horses, cattle, pigs, dogs, cats, rats and mice, or in vitro.

Certain preferred compounds of the present  
30 invention are characterized by their ability to inhibit thrombus formation with acceptable effects on classical measures of coagulation parameters, platelets and platelet function, and acceptable levels of bleeding complications associated with their use. Conditions  
35 characterized by undesired thrombosis would include those involving the arterial and venous vasculature.

-28-

With respect to the coronary arterial vasculature, abnormal thrombus formation characterizes the rupture of an established atherosclerotic plaque which is the major cause of acute myocardial infarction and unstable angina, as well as also characterizing the occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty (PTCA).

With respect to the venous vasculature, abnormal thrombus formation characterizes the condition observed in patients undergoing major surgery in the lower extremities or the abdominal area who often suffer from thrombus formation in the venous vasculature resulting in reduced blood flow to the affected extremity and a predisposition to pulmonary embolism. Abnormal thrombus formation further characterizes disseminated intravascular coagulopathy commonly occurs within both vascular systems during septic shock, certain viral infections and cancer, a condition wherein there is rapid consumption of coagulation factors and systemic coagulation which results in the formation of life-threatening thrombi occurring throughout the microvasculature leading to widespread organ failure.

Certain of the polymeric formulations of the present invention, incorporating cardiovascular drugs, prepared and used as disclosed herein, are believed to be useful for preventing or treating a condition characterized by undesired thrombosis, such as (a) the treatment or prevention of any thrombotically mediated acute coronary syndrome including myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, (b) the treatment or prevention of any thrombotically mediated cerebrovascular syndrome including embolic stroke,

thrombotic stroke or transient ischemic attacks, (c) the treatment or prevention of any thrombotic syndrome occurring in the venous system including deep venous thrombosis or pulmonary embolus occurring either  
5 spontaneously or in the setting of malignancy, surgery or trauma, (d) the treatment or prevention of any coagulopathy including disseminated intravascular coagulation (including the setting of septic shock or other infection, surgery, pregnancy, trauma or  
10 malignancy and whether associated with multi-organ failure or not), thrombotic thrombocytopenic purpura, thromboangitis obliterans, or thrombotic disease associated with heparin induced thrombocytopenia, (e) the treatment or prevention of thrombotic complications  
15 associated with extracorporeal circulation (e.g. renal dialysis, cardiopulmonary bypass or other oxygenation procedure, plasmapheresis), (f) the treatment or prevention of thrombotic complications associated with instrumentation (e.g. cardiac or other intravascular  
20 catheterization, intra-aortic balloon pump, coronary stent or cardiac valve), and (g) those involved with the fitting of prosthetic devices.

Anticoagulant therapy is also useful to prevent coagulation of stored whole blood and to  
25 prevent coagulation in other biological samples for testing or storage. Thus the polymeric cardiovascular drug formulation embodiments of this invention can be used in any environment in which it is desired that blood coagulation be inhibited, e.g., by incorporation  
30 into material such as vascular grafts, stents, orthopedic prostheses, cardiac stents, valves and prostheses, extra corporeal circulation systems and the like.

While many of the embodiments discussed above  
35 describe incorporation of drugs having cardiovascular effects, the invention is not so limited. Practically

any therapeutic agent having water-solubility and other characteristics suitable for the practice of this invention, for a variety of therapeutic applications are acceptable.

5           The following non-limiting examples set forth herein below illustrate certain aspects of the invention. All parts and percentages are by weight unless otherwise noted and all temperatures are in degrees Celsius. The PAI peptide was obtained from COR  
10 Therapeutics of South San Francisco, California. Poly(DTH adipate) was prepared according to the procedure provided in Example No. 2 of U.S. Patent No. 5,216,115. PEG was obtained from Aldrich Chemicals Milwaukee, WI. The drug and polymers were used without  
15 further purification. Solvents were of "HPLC grade" and were obtained from Fisher Scientific, Pittsburgh, PA.

#### EXAMPLES

20           The following examples are divided into two sections. In the section labeled as "Preferred Methods," the teachings disclosed in this invention are used to prepare release formulations with different release rates. In the second section, labeled as  
25 "Comparative Examples," methods known in the prior art are used to prepare similar release devices as those described in the first section. However, the release data obtained demonstrate that the methods known in the prior art provided significantly less suitable release profiles.

PREFERRED METHODSEXAMPLE 1

PREPARATION OF A PAI PEPTIDE CONTAINING  
RELEASE DEVICE WITH 10 WEIGHT PERCENT LOADING  
5 OF PEG ( $M_w=1,000$  da) AND 30 WEIGHT PERCENT  
LOADING OF PAI PEPTIDE USING THE MOST  
PREFERRED METHODS

PRECIPITATION

One of the above-listed PAI peptides (0.16 g)  
10 and PEG (0.057 g;  $M_w=1,000$ ) were each dissolved in  
methanol (7.0 ml and 1.0 ml respectively). Poly(DTH  
adipate) (0.32 g,  $M_w=110,000$ ) was dissolved in methylene  
chloride (7.0 ml). The peptide solution was pipetted  
15 into the PEG solution, then this mixture was pipetted  
into the poly(DTH adipate) solution. The resulting  
homogeneous solution was then dripped into stirred  
diethyl ether (140 ml) which was cooled by a dry ice-  
acetone bath. A white flocculent precipitate was  
20 formed which was isolated by careful filtration using a  
sintered glass funnel. After drying under a high  
vacuum at ambient temperature, 0.43 g of white solid  
material was recovered.

FILM FABRICATION

The completely dried PAI peptide-PEG-poly(DTH  
25 adipate) precipitate (0.43 g) was carefully cut on a  
clean dry surface into small pieces and transferred to  
a mold (4.0 cm x 4.0 cm x 0.1 mm, polished stainless  
steel surface). No release substances were applied to  
the mold. The material was compression molded into a  
30 film of a thickness in the range of 0.10-0.15 mm with  
the compression cycle shown in Table I. Upon removal  
from the mold, the film was translucent and pliable.

TABLE I  
COMPRESSION MOLDING FABRICATION  
CYCLE FOR THE PREPARATION OF FILMS  
CONSISTING OF PAI PEPTIDE-PEG-POLY(DTH ADIPATE)

5	TEMPERATURE (°C)	PRESSURE (psi)	TIME (MINUTES)
	Ambient to 95°	300	7
	95°	6000	6
	95-21°	6000	20

10 TOTAL PAI PEPTIDE LOADING

Three pieces (total recorded weight of 5-6 mg) were cut from different regions of PAI peptide loaded film and placed into a 10 ml volumetric flask. Tetrahydrofuran (0.5 ml) was added to dissolve the polymer and to liberate the entrapped PAI peptide. After the pieces of film had completely disintegrated and a white solid was evident, the volumetric flask was filled to the 10 ml level with phosphate buffer (9.5 ml) and gently agitated. An aliquot (1 ml) was pipetted from the flask, filtered (0.45 µm syringe filter), and analyzed for PAI peptide content by HPLC. The experimentally determined amount of PAI peptide found in the films was within ten percent of the theoretically expected amount.

25 PAI PEPTIDE IN-VITRO RELEASE

A device (9.97 x 15.6 mm, 55.1 mg) was cut from a PAI peptide-PEG-poly(DTH adipate) film, placed into a capped vial containing phosphate buffer (10 ml, 37°C), and incubated in a shaker bath at 37°C. After 15 minutes, the device was transferred using forceps to another capped vial containing phosphate buffer (10 ml, 37°C) and the device was further incubated in the shaker bath. This process was repeated every 15 minutes for the first hour, every 30 minutes for the second hour, then hourly until four hours. The device

can be further incubated in phosphate buffer if longer time points are desired. Aliquots of the respective release media (1 ml) were removed from each vial, filtered, and the PAI peptide content was assayed by HPLC analysis. The release profile is compiled in Table II.

TABLE II  
24-HOUR IN VITRO RELEASE PROFILE OF PAI PEPTIDE  
FROM A DEVICE FORMULATED WITH 10 WEIGHT PERCENT OF  
PEG ( $M_w=1,000$  da) AND 30 WEIGHT PERCENT OF PAI PEPTIDE

Time (min.)	Amt. Released (mg)	Cumul. Rel. (mg)	% Rel.	Cumul. % Rel.	Release rate in mg/cm <sup>2</sup>	Release rate in µg/cm <sup>2</sup> min
15	1.82	1.82	11.03	11.03	0.586	39.09
30	0.39	2.22	2.39	13.43	0.127	8.48
45	0.25	2.47	1.53	14.95	0.081	5.41
60	0.14	2.61	0.87	15.82	0.046	3.07
90	0.17	2.79	1.07	16.89	0.056	1.90
120	0.17	2.96	1.04	17.93	0.055	1.84
180	0.21	3.17	1.27	19.20	0.067	1.13
240	0.26	3.44	1.61	20.81	0.085	1.43
480	0.38	3.82	2.32	23.14	0.123	0.51
1440	0.77	4.59	4.65	27.78	0.247	0.26

The translucent and foggy appearance of the film indicated that phase-separated microdomains had formed. In this study, the targeted minimum release rate for PAI peptide was 0.2 micrograms/cm<sup>2</sup>min. Release rates between 0.01 and 100 micrograms/cm<sup>2</sup>min are suitable for use in the present invention. Release rates between 0.10 and 10 micrograms/cm<sup>2</sup>min are preferred. Table II illustrates that this formulation surpassed the minimum release rate throughout the 24-hour release study. The burst effect was significantly reduced compared to formulations prepared according to procedures known in the prior art.

EXAMPLE 2

PREPARATION OF A PAI PEPTIDE CONTAINING  
RELEASE DEVICE WITH 7 WEIGHT PERCENT LOADING  
OF PEG ( $M_w=1,000$  da) AND 30 WEIGHT PERCENT  
5 LOADING OF PAI PEPTIDE USING THE MOST  
PREFERRED METHODS.

PRECIPITATION

PAI peptide (0.4 g) and PEG (0.100 g;  
 $M_w=1,000$ ) were each dissolved in methanol (10.0 ml and  
10 1.0 ml respectively). Poly(DTH adipate) (0.84 g,  
 $M_w=110,000$ ) was dissolved in methylene chloride (10.0  
ml). The PAI peptide solution was pipetted into the  
PEG solution, then this mixture was pipetted into the  
poly(DTH adipate) solution. The resulting homogeneous  
15 solution was then dripped into stirred diethyl ether  
(150 ml) which was cooled by a dry ice-acetone bath. A  
white flocculent precipitate was formed which was  
isolated by careful filtration using a sintered glass  
funnel. After drying under high vacuum at ambient  
20 temperature 1.04 g of a white solid material was  
recovered.

FILM FABRICATION

The completely dried PAI peptide-PEG-poly(DTH  
adipate) precipitate (0.40 g) was fabricated into a  
25 compression molded film as described in Example 1,  
using the compression profile shown in Table I. Upon  
removal from the mold, the film was translucent and  
pliable. Total PAI peptide loading was confirmed by  
HPLC analysis.

30 PAI PEPTIDE IN-VITRO RELEASE

A device (4.88 x 11.90 mm, 11.3 mg) was cut  
from a PAI peptide-PEG-poly (DTH adipate) film loaded  
with 30 weight percent PAI peptide and 7 weight percent  
PEG. The release of PAI peptide was determined over a  
35 17-hour period as described in Example 1. The release  
data are summarized in Table III.

TABLE III  
17-HOUR IN VITRO RELEASE PROFILE  
OF PAI PEPTIDE FROM A DEVICE FORMULATED  
WITH 7 WEIGHT PERCENT OF PEG ( $M_w=1,000$  da) AND 30 WEIGHT  
PERCENT OF PAI PEPTIDE

Time (min.)	Amt. Released (mg)	Cumul. Rel. (mg)	% Rel.	Cumul. % Rel.	Release rate in mg/cm <sup>2</sup>	Release rate in µg/cm <sup>2</sup> min
15	0.17	0.17	5.08	5.08	0.14	9.55
30	0.04	0.21	1.29	6.37	0.04	2.42
60	0.09	0.30	2.72	9.09	0.07	2.55
300	0.12	0.42	3.74	12.83	0.10	0.44
1020	0.14	0.56	4.24	17.07	0.12	0.17

Table III illustrates that the release rate for PAI peptide was significantly lower in this example than in Example 1. This is in accordance with the teachings of this invention and illustrates that the release rate decreases when the amount of second, phase-disrupting polymer added into the formulation is reduced.

#### EXAMPLE 3

PREPARATION OF A PAI PEPTIDE CONTAINING RELEASE DEVICE WITH 14 WEIGHT PERCENT LOADING OF PEG ( $M_w=1,000$  da) AND 30 WEIGHT PERCENT LOADING OF PAI PEPTIDE USING THE MOST PREFERRED METHODS.

#### PRECIPITATION

PAI peptide (0.2 g) and PEG (0.097 g;  $M_w=1,000$ ) were each dissolved in methanol (7.0 ml and 1.0 ml respectively). Poly(DTH adipate) (0.37 g,  $M_w=110,000$ ) was dissolved in methylene chloride (7.0 ml). The PAI peptide solution was pipetted into the PEG solution, then this mixture was pipetted into the poly(DTH adipate) solution. The resulting homogeneous solution was then dripped into stirred diethyl ether

(140 ml) which was cooled by a dry ice-acetone bath. A white flocculent precipitate was formed which was isolated by careful filtration using a sintered glass funnel. After drying under high vacuum at ambient temperature, 0.54 g of a white solid material was recovered.

#### FILM FABRICATION

The completely dried PAI peptide-PEG-poly(DTH adipate) precipitate (0.45 g) was fabricated into a compression molded film as described in Example 1, using the compression profile shown in Table I. Upon removal from the mold, the film was translucent and pliable. Total PAI peptide loading was confirmed by HPLC analysis.

#### PAI PEPTIDE IN-VITRO RELEASE

A device (1.25 x 2.00 cm, 81.4 mg) was cut from an PAI peptide-PEG-poly(DTH adipate) film loaded with 30 weight percent PAI peptide and 14 weight percent PEG. The release of PAI peptide was determined over a 2-hour period as described in Example I. The release data are summarized in Table IV.

TABLE IV

#### 2-HOUR IN VITRO RELEASE PROFILE OF PAI PEPTIDE

RELEASE FROM A DEVICE FORMULATED WITH 14 WEIGHT PERCENT OF PEG ( $M_w=1,000$  da) AND 30 WEIGHT PERCENT OF PAI PEPTIDE

Time (min.)	Amt. Released (mg)	Cumul. Rel. (mg)	% Rel.	Cumul. % Rel.	Release rate in mg/cm <sup>2</sup>	Release rate in µg/cm <sup>2</sup> min
15	13.56	13.56	55.58	55.58	2.72	180.81
30	1.88	15.44	7.70	63.28	0.37	25.06
45	0.57	16.01	2.35	65.63	0.11	7.65
60	0.23	16.25	0.97	66.60	0.05	3.16
90	0.35	16.61	1.46	68.06	0.07	2.37
120	0.15	16.76	0.63	68.69	0.03	1.02

Table IV illustrates that the release rate for PAI peptide was significantly increased in this example in comparison to Example 1. This is in accordance with the teachings of this invention and illustrates that the release rate increases when the amount of second, phase-disrupting polymer added into the formulation is increased.

#### EXAMPLE IV

PREPARATION OF A PAI PEPTIDE CONTAINING  
RELEASE DEVICE CONTAINING A 30 WEIGHT PERCENT  
LOADING OF PAI PEPTIDE AND A 14 WEIGHT  
PERCENT LOADING OF PEG ( $M_w=20,000$  da) USING  
THE MOST PREFERRED METHODS.

#### PRECIPITATION

PAI peptide (0.2 g) and PEG (0.097 g;  $M_w=20,000$  da) were each dissolved in methanol (7.0 ml and 1.0 ml respectively). Poly(DTH adipate) (0.37 g,  $M_w=110,000$ ) was dissolved in methylene chloride (7.0 ml). The PAI peptide solution was pipetted into the PEG solution, then this mixture was pipetted into the poly(DTH adipate) solution. The resulting homogeneous solution was then dripped into stirred diethyl ether (140 ml) which was cooled by a dry ice-acetone bath. A white flocculent precipitate was formed which was isolated by careful filtration using a sintered glass funnel. After drying under high vacuum at ambient temperature 0.59 g of a white solid material was recovered.

#### FILM FABRICATION

The completely dried PAI peptide-PEG-poly(DTH adipate) precipitate (0.43 g) was fabricated into a compression molded film as described in Example 1, using the compression profile shown in Table I. Upon removal from the mold, the film was translucent and pliable. Total PAI peptide loading was confirmed by HPLC analysis.

PAI PEPTIDE IN-VITRO RELEASE

A device (1.25 x 2.00 cm, 52.0 mg) was cut from a PAI peptide-PEG-poly(DTH adipate) film loaded with 30 weight percent PAI peptide and 14 weight percent PEG ( $M_w = 20,000$ ). The release of PAI peptide was determined over a 24-hour period as described in Example 1. The release data are summarized in Table V.

TABLE V24-HOUR IN VITRO RELEASE PROFILEOF PAI PEPTIDE FROM A DEVICE FORMULATEDWITH 14 WEIGHT PERCENT OF PEG ( $M_w=20,000$  da) AND30 WEIGHT PERCENT OF PAI PEPTIDE

Time (min.)	Amt. Released (mg)	Cumul. Rel. (mg)	% Rel.	Cumul. % Rel.	Release rate in mg/cm <sup>2</sup>	Release rate in μg/cm <sup>2</sup> min
15	4.06	4.06	23.09	23.09	0.81	54.19
30	1.25	5.31	7.09	30.18	0.25	16.74
45	0.36	5.67	2.03	32.21	0.07	4.77
60	0.26	5.93	1.47	33.68	0.05	3.45
90	0.34	6.28	1.97	35.66	0.07	2.32
120	0.25	6.53	1.42	37.08	0.05	1.67
150	0.19	6.72	1.13	38.21	0.04	1.32
180	0.14	6.86	0.80	39.00	0.03	0.93
240	0.25	7.12	1.43	40.44	0.05	0.84
300	0.18	7.30	1.02	41.46	0.04	0.60
420	0.24	7.53	1.35	42.81	0.05	0.40
1440	0.53	8.06	3.01	45.82	0.10	0.10

The device of this example is identical in all aspects to the device described in Example 3, except that the phase-disrupting polymer had a higher molecular weight. Comparison of Table V with Table IV illustrates the effect of the molecular weight of the phase-disrupting polymer on the observed release rate. In this particular example, increasing the molecular weight of the phase-disrupting polymer resulted in a

reduction of the initial burst and reduction in the overall release rate over a 24-hour interval.

#### MASS BALANCE CONFIRMATION

##### AFTER COMPLETION OF THE RELEASE PERIOD

5           After the 24-hour release study the amount of PAI peptide entrapped in the film was determined by first, removal of the device from the phosphate buffer, then dissolving the device in tetrahydrofuran (2 ml) in a 10 ml volumetric flask. After the film had  
10 completely disintegrated and a white solid was evident, the volumetric flask was filled to the 10 ml level with phosphate buffer (8.0 ml) and gently agitated. An aliquot (1 ml) was pipetted from the flask, filtered (0.45 micron syringe filter), and analyzed for PAI  
15 peptide content by HPLC. The experimentally determined amount of PAI peptide found in the film was equivalent to the amount of PAI peptide expected to be entrapped in the film based on the amount released over the 24-hour test period. This result confirms the internal  
20 consistency of the analytical methods used to measure and calculate the release of PAI peptide from release devices.

#### EXAMPLE 5

25           PREPARATION OF A 25 WEIGHT PERCENT PAI PEPTIDE DEVICE WITHOUT PHASE-DISRUPTING POLYMER ADDED USING THE MOST PREFERRED METHODS

##### PRECIPITATION

30           PAI peptide (0.14 g) was dissolved in methanol (7.0 ml). Poly(DTH adipate) (0.421 g,  $M_w=110,000$ ) was dissolved in methylene chloride (5.0 ml). The PAI peptide solution was pipetted into the poly(DTH adipate) solution. The resulting homogeneous solution was then dripped into stirred diethyl ether  
35 (100 ml) which was cooled by a dry ice-acetone bath. A white flocculent precipitate was formed which was

isolated by careful filtration using a sintered glass funnel. After drying under high vacuum at ambient temperature, a white solid material was recovered.

#### FILM FABRICATION

5 The completely dried PAI peptide-poly(DTH adipate) precipitate (0.41 g) was fabricated into a compression molded film as described in Example 1, using the compression profile shown in Table I. Upon removal from the mold, the film was transparent and  
10 pliable. Total PAI peptide loading was confirmed by HPLC analysis.

#### PAI PEPTIDE IN-VITRO RELEASE

A device (6.3 x 6.7 mm, 12.4 mg) was cut from a PAI peptide-poly(DTH adipate) film loaded with 25  
15 weight percent PAI peptide. The release of PAI peptide was determined over a 4-hour period as described in Example 1. The release data are summarized in Table VI.

TABLE VI

#### 4-HOUR IN VITRO RELEASE

#### PROFILE OF PAI PEPTIDE FROM A DEVICE

#### FORMULATED WITH 25 WEIGHT PERCENT OF PAI PEPTIDE

Time (min.)	Amt. Released (mg)	Cumul. Rel. (mg)	% Rel.	Cumul. % Rel.	Release rate in mg/cm <sup>2</sup>	Release rate in µg/cm <sup>2</sup> min
30	0.007	0.007	0.21	0.21	0.008	0.26
60	0.004	0.011	0.13	0.34	0.004	0.15
120	0.001	0.012	0.03	0.37	0.001	0.02
240	0.001	0.013	0.04	0.41	0.001	0.01

25  
30 Table VI illustrates that essentially no PAI peptide release occurred over the four-hour test period. In a further study of the PAI peptide release from devices formulated without PEG, the release period  
35 was extended to 30 days. It was found that less than 5 percent of the PAI peptide loading was released over

-41-

a 30-day period. This is unexpected based on teachings in the prior art, considering that PAI peptide is a hydrophilic, readily water-soluble drug. Based on prior art teachings, a 30 weight percent loading of a water-soluble drug should have resulted in a significant burst effect followed by release of the drug.

#### COMPARATIVE EXAMPLES

##### EXAMPLE 6

10 FORMULATION OF AN EVA RELEASE DEVICE AT A PAI  
PEPTIDE LOADING OF 10 WEIGHT PERCENT  
ACCORDING TO THE PRIOR ART METHOD OF LANGER.

##### FILM FABRICATION

450 mg of EVA was dissolved in 20 ml of  
15 methylene chloride. While vigorously stirring the  
polymer solution, solid PAI peptide (50 mg which had  
previously been ground by mortar and pestle under dry  
conditions and sieved through a "270" mesh) was slowly  
added. A milky solution was formed in which the drug  
20 was well dispersed. In an atmosphere of nitrogen, the  
suspension was poured into a glass mold which had been  
pre-cooled over a dry ice-acetone mixture. The  
circular glass mold was covered with filter paper to  
facilitate the slow, overnight evaporation of the  
25 solvent. For further drying, the mold was kept under  
high vacuum for four hours. Then the film was  
separated from the mold. To remove additional traces  
of solvent trapped within the polymeric matrix, the  
film was placed between two tissue papers and kept  
30 under high vacuum at ambient temperature for a minimum  
of three days.

##### PAI PEPTIDE IN-VITRO RELEASE

Samples were cut from the dry EVA-PAI peptide  
loaded films. The release of PAI peptide was  
35 determined over a four-hour period as described in  
Example 1. Films that were of the clinically useful

thickness of 0.10-0.20 mm were characterized by excessively strong initial bursts of greater than 90 percent of the loaded PAI peptide being released in the first 10 minutes. Such films are clearly unacceptable for the development of a clinically useful device formulation.

In this example, polyethylene-vinyl acetate co-polymer (EVA) was used as a model polymer and film formulations were prepared as described in the seminal work of Langer (Siegel and Langer, J. Contrl. Rel., 14, 153-67 (1990)). This is the method most commonly used in the prior art. The release profiles obtained with such films illustrate the difficulties encountered when water-soluble drugs are incorporated into polymeric films by the methods known in the prior art.

#### EXAMPLE 7

FORMULATION OF A RELEASE DEVICE AT A PAI  
PEPTIDE LOADING OF 20 WEIGHT PERCENT  
ACCORDING TO THE PRIOR ART METHOD OF LANGER.

#### 20 FILM FABRICATION

Poly(DTH sebacate) [a member of the family of polyarylates] and 71 mg of PAI peptide were used to prepare a suspension cast film of polymer and drug as described for Example 6.

#### 25 PAI PEPTIDE IN-VITRO RELEASE

Samples were cut from the dry poly(DTH sebacate)-PAI peptide loaded films. The release of PAI peptide was determined over a 30-day period as described in Example 1.

30 The film samples obtained according to Example 7 released 84 percent of the total PAI peptide loading within three hours. The remaining 16 percent of the drug loading were permanently entrapped within the film and were not released even over a 30-day  
35 period. Such formulations are clearly inferior to the

systems obtained according to the preferred methods of this invention as illustrated in Examples 1 through 4.

The foregoing examples and description of the preferred embodiment should be taken as illustrating, rather than as limiting, the present invention as defined by the claims. As will be readily appreciated, numerous variations and combinations of the features set forth above can be utilized without departing from the present invention as set forth in the claims. Such variations are not regarded as a departure from the spirit and scope of the invention, and all such modifications are intended to be included within the scope of the following claims.

WHAT IS CLAIMED IS

1. A polymeric drug formulation characterized by a non-releasing single-phase dispersion of a water-soluble drug in a water-insoluble tissue-compatible polymer matrix.

2. A method of forming a single-phase dispersion of a water-soluble drug with a water-insoluble tissue-compatible polymer characterized by:

blending a water-soluble drug with a water-insoluble tissue-compatible polymer that is miscible in the solid phase with said drug in a solvent system capable of forming a homogeneous solution of said drug and said polymer; and

adding said solution to an amount of a non-solvent for said drug and said polymer, so that said drug and said polymer coprecipitate from said solution as a solid single-phase dispersion of said drug and said polymer.

3. The method of claim 2, characterized in that said blending step comprises dissolving said water-soluble drug in a first solvent in which said drug is soluble, dissolving said tissue-compatible polymer in a second solvent in which said polymer is soluble, and combining said first and second solvent solutions, wherein said first solvent and said second solvent are capable of forming a homogeneous solution with each other and said drug and said polymer.

4. The method of claim 2, characterized in that said drug and said polymer are each dissolved in said solvent system at a level between about 1 and about 30 percent by weight.

5. The method of claim 2, characterized in that said non-solvent is selected from the group consisting of diethyl ether, diisopropyl ether, methyl t-butyl ether, methyl ethyl ketone, acetonitrile, toluene, xylene and carbon tetrachloride.

6. The method of claim 2, characterized in that said solution of said drug and said polymer is added to at least 5 to 10 volumes of said non-solvent compared to the volume of said solvent system.

5 7. The method of claim 2, characterized in that said non-solvent is chilled to a temperature as low as the freezing point of said nonsolvent.

8. A polymeric drug formulation characterized by a single-phase dispersion of a water-soluble drug in a water-insoluble tissue-compatible polymer matrix, and a second, phase-disrupting polymer that is non-miscible with said tissue-compatible polymer and is present in an amount sufficient to form phase-separated microdomains of said second polymer in  
10 said tissue-compatible polymer matrix, so that the release rate of said water-soluble drug from said tissue-compatible polymer matrix is related to said  
15 amount of said second polymer.

9. The polymeric drug formulation of  
20 claims 1 or 8 characterized in that said tissue-compatible polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers thereof, poly(ethylene-co-vinyl acetate), poly(caprolactone), poly(orthoesters), poly(carbonates),  
25 poly(arylates), poly(iminocarbonates), poly(vinylpyrrolidone), pyran copolymer, poly(hydroxypropyl-methacrylamide-phenol), poly(hydroxy-ethyl-aspartamide-phenol), poly(ethylene oxide)-poly(lysine) substituted with palmitoyl residues, poly(hydroxybutyric acid),  
30 poly(acetals), poly(dihydropyran), poly(cyanoacrylates) and cross-linked and amphipathic block copolymers of hydrogels.

10. The polymeric drug formulation of  
claim 9, characterized in that said tissue-compatible  
35 polymer is a poly(arylate).

11. The polymeric drug formulation of claim 10, characterized in that said polyarylate is poly(desaminotyrosyl-tyrosine hexyl ester adipate).

12. The polymeric drug formulation of claims 1 or 8, characterized in that said water-soluble drug is a non-peptide drug selected from the group consisting of natural and unnatural antibiotics, cytotoxic agents and oligonucleotides.

13. The polymeric drug formulation of claims 1 or 8, characterized in that said water-soluble drug is a peptide drug selected from the group consisting of immunoglobulins, immunoglobulin fragments and platelet aggregation inhibiting peptides.

14. The polymeric drug formulation of claim 13, characterized in that said peptide drug is a platelet aggregation inhibiting peptide.

15. The polymeric drug formulation of claims 1 or 8, characterized by a drug loading up to about 50 percent by weight.

16. The polymeric drug formulation of claim 15, characterized by a drug loading up to about 30 percent by weight.

17. The polymeric drug formulation of claim 16, characterized by a drug loading between about 10 and about 20 percent by weight.

18. The polymeric drug formulation of claim 8, characterized in that said second, phase-disrupting polymer is selected from the group consisting of poly(alkylene oxides), polysaccharides, poly(vinyl alcohol), poly(pyrrolidone), poly(acrylic acids) and poly(acrylic acid esters).

19. The polymeric drug formulation of claim 18, characterized in that said second, phase-disrupting polymer is poly(ethylene glycol).

20. The polymeric drug formulation of claim 8, characterized in that said second, phase-

disrupting polymer is present at a level between about 2 and about 30 percent by weight.

21. A method of forming a polymeric drug formulation characterized by:

5                   blending a water-soluble drug with a water-insoluble tissue-compatible polymer that is miscible in the solid phase with said drug, and with a second, phase-disrupting polymer that is non-miscible with said tissue-compatible polymer, in a solvent  
10 system capable of forming a homogeneous solution of said drug, said tissue-compatible polymer and said second, phase-disrupting polymer; and

                  adding said solution to an amount of a non-solvent for said drug, said tissue-compatible polymer  
15 and said second, phase-disrupting polymer, so that a microdomain-separated solid co-precipitate of said drug, said tissue-compatible polymer and said second, phase-disrupting polymer is formed, wherein said second, phase-disrupting polymer is blended in an  
20 amount effective to form phase-separated microdomains in said co-precipitate.

22. The method of claims 2 or 21, characterized in that said tissue-compatible polymer is selected from the group consisting of poly(lactic  
25 acid), poly(glycolic acid), and copolymers thereof, poly(ethylene-co-vinyl acetate), poly(caprolactone), poly(orthoesters), poly(carbonates), poly(arylates), poly(iminocarbonates), poly(vinylpyrrolidone), pyran copolymer, poly(hydroxypropyl-methacrylamide-phenol),  
30 poly(hydroxyethyl-aspartamide-phenol), poly(ethylene oxide)-poly(lysine) substituted with palmitoyl residues, poly(hydroxybutyric acid), poly(acetals), poly(dihydro-pyran), poly(cyanoacrylates) and cross-linked and amphipathic block copolymers of hydrogels.

35                   23. The method of claim 22, characterized in that said tissue-compatible polymer is a poly(arylate).

24. The method of claim 23, characterized in that said poly(arylate) is poly(desaminotyrosyl-tyrosine hexyl ester adipate).

25. The method of claims 2 or 21, characterized in that said water-soluble drug is a non-peptide drug selected from the group consisting of natural and unnatural antibiotics, cytotoxic agents and oligonucleotides.

26. The method of claims 2 or 21, characterized in that said water-soluble drug is a peptide drug selected from the group consisting of immunoglobulins, immunoglobulin fragments and platelet aggregation inhibiting peptides.

27. The method of claim 26, characterized in that said peptide drug is a platelet aggregation inhibiting peptide.

28. The method of claims 2 or 21, characterized by a drug loading up to about 50 percent by weight.

29. The method of claim 28, characterized by a drug loading up to about 30 percent by weight.

30. The method of claim 29, characterized by a drug loading between about 10 and about 20 percent by weight.

31. The method of claim 21, characterized in that said second, phase-disrupting polymer is selected from the group consisting of poly(alkylene oxides), polysaccharides, poly(vinyl alcohol), poly(pyrrolidone), poly(acrylic acids) and poly(acrylic acid esters).

32. The method of claim 31, characterized in that said second, phase-disrupting polymer is poly(ethylene glycol).

33. The method of claim 21, characterized in that said second, phase-disrupting polymer is present

at a level between about 2 and about 30 percent by weight.

34. The method of claim 21, characterized in that said blending step comprises dissolving said  
5 water-soluble drug in a first solvent in which said drug is soluble, dissolving said tissue-compatible polymer in a second solvent in which said polymer is soluble, and dissolving said second, phase-disrupting polymer in whichever of said first and second solvents  
10 said polymer is soluble; and combining said first and second solvent solutions, wherein said first solvent and said second solvent are capable of forming a homogeneous solution with each other, and said drug, said tissue-compatible polymer and said second, phase-disrupting polymer.  
15

35. The method of claims 2 or 21, characterized in that said solvent system comprises at least one solvent selected from the group consisting of methanol, methylene chloride, ethanol, ethylene glycol, glycerol, tetrahydrofuran, ethyl acetate, acetonitrile,  
20 acetone, diisopropyl ether, methyl t-butyl ether, chloroform, carbon tetrachloride, dichloroethane and water.

36. The method of claim 21, characterized in  
25 that said drug, said tissue-compatible polymer and said second, phase-disrupting polymer are each dissolved in said solvent system at a level between about 1 and about 30 percent by weight.

37. The method of claims 2 or 21,  
30 characterized in that said non-solvent is selected from the group consisting of diethyl ether, diisopropyl ether, methyl t-butyl ether, methyl ethyl ketone, acetonitrile, toluene, xylene and carbon tetrachloride.

38. The method of claim 21, characterized in  
35 that said solution of said drug, said tissue-compatible polymer and said second, phase-disrupting polymer is

added to at least 5 to 10 volumes of said non-solvent compared to the volume of said solvent system.

39. A polymeric drug formulation prepared by the method of claims 2 or 21.

5           40. The polymeric drug formulation of claim 39, characterized in that said water-soluble drug is a platelet aggregation inhibiting peptide.

10           41. A method for site-specific drug delivery characterized by implanting in the body of a patient in need thereof the polymeric drug formulation of claim 1 or claim 8.

42. The method of claim 41, characterized in that said water-soluble drug is a platelet aggregation inhibiting peptide.

15           43. The method of claim 42, characterized in that said polymeric drug formulation is implanted during or following a cardiovascular procedure in which a stent is inserted into an artery, and said implanting step comprises the step of placing a film of said drug  
20 formulation between the wall of said artery and said stent, so that local release of said platelet aggregation inhibiting peptide reduces the formation of blood clots at said stent insertion site.

25           44. The method of claim 42, characterized in that said polymeric drug formulation is implanted as a coating on the surface of a blood-contacting device or implant.

30           45. A blood-contacting device or implant coated with the polymeric drug formulation of claim 1 or claim 8, characterized in that said water-soluble drug is a platelet aggregation inhibiting peptide.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/11766

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 9/10, 47/30, 47/32, 47/34, 47/36

US CL :424/484, 487, 488

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/484, 487, 488

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 4,304,591 (MUELLER) 08 December 1981, entire document.	1-45

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

15 SEPTEMBER 1996

Date of mailing of the international search report

02 OCT 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

EDWARD J. WEBMAN

Telephone No. (703) 308-2351